So, while Inovio might be struggling at the moment, it's entirely possible that this is simply a good company getting swept up in a broader market trend. Monday's gains don't seem to have a specific news item motivating them and come amidst a 0.86-percent gain for the Nasdaq Comp. and a 1.4-percent gain for IBB and it would seem more than possible that Inovio's price is currently at the mercy of market forces out of its control. As such, the right news could provide just the catalyst needed to help Inovio break out and differentiate itself from broader small-cap biotech plays.